Search

Your search keyword '"Budd, G. Thomas"' showing total 7 results
Start Over Author "Budd, G. Thomas" Publication Year Range This year
7 results on '"Budd, G. Thomas"'

2. Adjunctive Statistical Standardization of Adjuvant Estrogen Receptor and Progesterone Receptor in Canadian Cancer Trials Group MA.27 Postmenopausal Breast Cancer Trial of Exemestane Versus Anastrozole.

Author

Chapman, Judith-Anne W., Bayani, Jane, SenGupta, Sandip, Bartlett, John M.S., Piper, Tammy, Quintayo, Mary Anne, Virk, Shakeel, Goss, Paul E., Ingle, James N., Ellis, Matthew J., Sledge, George W., Budd, G. Thomas, Rabaglio, Manuela, Ansari, Rafat H., Tozer, Richard, D'Souza, David P., Chalchal, Haji, Spadafora, Silvana, Stearns, Vered, and Perez, Edith A.

Published
2024
Full Text
View/download PDF

3. Supplementary Table S1 from Phase II Clinical Trial of Pembrolizumab and Chemotherapy Reveals Distinct Transcriptomic Profiles by Radiologic Response in Metastatic Triple-Negative Breast Cancer

Author

Wilkerson, Avia D., primary, Parthasarathy, Prerana Bangalore, primary, Stabellini, Nickolas, primary, Mitchell, Carley, primary, Pavicic, Paul G., primary, Fu, Pingfu, primary, Rupani, Amit, primary, Husic, Hana, primary, Rayman, Patricia A., primary, Swaidani, Shadi, primary, Abraham, Jame, primary, Budd, G. Thomas, primary, Moore, Halle, primary, Al-Hilli, Zahraa, primary, Ko, Jennifer S., primary, Baar, Joseph, primary, Chan, Timothy A., primary, Alban, Tyler, primary, Diaz-Montero, C. Marcela, primary, and Montero, Alberto J., primary

Published
2024
Full Text
View/download PDF

4. Supplementary Figure S5 from Phase II Clinical Trial of Pembrolizumab and Chemotherapy Reveals Distinct Transcriptomic Profiles by Radiologic Response in Metastatic Triple-Negative Breast Cancer

Author

Wilkerson, Avia D., primary, Parthasarathy, Prerana Bangalore, primary, Stabellini, Nickolas, primary, Mitchell, Carley, primary, Pavicic, Paul G., primary, Fu, Pingfu, primary, Rupani, Amit, primary, Husic, Hana, primary, Rayman, Patricia A., primary, Swaidani, Shadi, primary, Abraham, Jame, primary, Budd, G. Thomas, primary, Moore, Halle, primary, Al-Hilli, Zahraa, primary, Ko, Jennifer S., primary, Baar, Joseph, primary, Chan, Timothy A., primary, Alban, Tyler, primary, Diaz-Montero, C. Marcela, primary, and Montero, Alberto J., primary

Published
2024
Full Text
View/download PDF

5. Data from Phase II Clinical Trial of Pembrolizumab and Chemotherapy Reveals Distinct Transcriptomic Profiles by Radiologic Response in Metastatic Triple-Negative Breast Cancer

Author

Wilkerson, Avia D., primary, Parthasarathy, Prerana Bangalore, primary, Stabellini, Nickolas, primary, Mitchell, Carley, primary, Pavicic, Paul G., primary, Fu, Pingfu, primary, Rupani, Amit, primary, Husic, Hana, primary, Rayman, Patricia A., primary, Swaidani, Shadi, primary, Abraham, Jame, primary, Budd, G. Thomas, primary, Moore, Halle, primary, Al-Hilli, Zahraa, primary, Ko, Jennifer S., primary, Baar, Joseph, primary, Chan, Timothy A., primary, Alban, Tyler, primary, Diaz-Montero, C. Marcela, primary, and Montero, Alberto J., primary

Published
2024
Full Text
View/download PDF

7. Phase II Clinical Trial of Pembrolizumab and Chemotherapy Reveals Distinct Transcriptomic Profiles by Radiologic Response in Metastatic Triple-Negative Breast Cancer.

Author

Wilkerson AD, Parthasarathy PB, Stabellini N, Mitchell C, Pavicic PG Jr, Fu P, Rupani A, Husic H, Rayman PA, Swaidani S, Abraham J, Budd GT, Moore H, Al-Hilli Z, Ko JS, Baar J, Chan TA, Alban T, Diaz-Montero CM, and Montero AJ

Subjects
Humans, Antibodies, Monoclonal, Humanized pharmacology, Antineoplastic Combined Chemotherapy Protocols adverse effects, Gene Expression Profiling, Progression-Free Survival, Triple Negative Breast Neoplasms drug therapy, Triple Negative Breast Neoplasms genetics, Triple Negative Breast Neoplasms pathology
Abstract

Purpose: A single arm, phase II trial of carboplatin, nab-paclitaxel, and pembrolizumab (CNP) in metastatic triple-negative breast cancer (mTNBC) was designed to evaluate overall response rate (ORR), progression-free survival (PFS), duration of response (DOR), safety/tolerability, overall survival (OS), and identify pathologic and transcriptomic correlates of response to therapy., Patients and Methods: Patients with ≤2 prior therapies for metastatic disease were treated with CNP regardless of tumor programmed cell death-ligand 1 status. Core tissue biopsies were obtained prior to treatment initiation. ORR was assessed using a binomial distribution. Survival was analyzed via the Kaplan-Meier method. Bulk RNA sequencing was employed for correlative studies., Results: Thirty patients were enrolled. The ORR was 48.0%: 2 (7%) complete responses (CR), 11 (41%) partial responses (PR), and 8 (30%) stable disease (SD). The median DOR for patients with CR or PR was 6.4 months [95% confidence interval (CI), 4-8.5 months]. For patients with CR, DOR was >24 months. Overall median PFS and OS were 5.8 (95% CI, 4.7-8.5 months) and 13.4 months (8.9-17.3 months), respectively. We identified unique transcriptomic landscapes associated with each RECIST category of radiographic treatment response. In CR and durable PR, IGHG1 expression was enriched. IGHG1high tumors were associated with improved OS (P = 0.045) and were concurrently enriched with B cells and follicular helper T cells, indicating IGHG1 as a promising marker for lymphocytic infiltration and robust response to chemo-immunotherapy., Conclusions: Pretreatment tissue sampling in mTNBC treated with CNP reveals transcriptomic signatures that may predict radiographic responses to chemo-immunotherapy., (©2023 The Authors; Published by the American Association for Cancer Research.)

Published
2024
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results